A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism
← catalyst calendarNCT07377474 · readout ≤ 406 d
Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
32estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Apr 2026 | estimated | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myopic Astigmatism
Intervention
- Device: TENEO 317 Model 2 (1.28 US) Excimer Laser
Primary outcomes
what the primary-completion date above is the date OFThe percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 0.50 D
measured Assessed for approximately 12 months
The percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 1.00 D
measured Assessed for approximately 12 months
The percentage of eyes that achieve a UDVA of 20/40 or better
measured Assessed for approximately 12 months
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed